TACSTD2 and prostate carcinoma: To achieve this, we generated spheroids from the LNCaP, DU-145, and LAPC4 prostate cancer cell lines, with varying levels of surface TROP-2 expression (low, medium, and high, respectively) (Fig. 7B) and incorporated them into the hydrogel of a LumeNEXT device, as described previously.